PROPHYLAXIS
-
Approvals of Hemlibra – The devil is in the details
Montreal, September 13, 2021 – In recent weeks, governments in both Quebec and the rest of Canada have expanded access to Hemlibra to patients with...
-
CHS 2020 Annual Report
CLICK HERE to access the CHS 2020 Annual Report and the complete Financial Statements.
-
CHS replies to Quebec’s INESSS following its shocking report on the funding of Hemlibra
The Institut national d’excellence en santé et en services sociaux (INESSS) released its recommendation on funding Hemlibra (emicizumab) for the treatment of severe hemophilia A...
-
A Patient Videoconference on Inhibitors & New Novel Therapies – Answering Your Questions!
On November 2, 2020, the CHS held a live educational videoconference aimed to improve the understanding of FVIII/FIX inhibitors and treatment options, with a...
-
WFH publishes 3rd Edition of the Guidelines for the Management of Hemophilia
The World Federation of Hemophilia (WFH) has published the 3rd Edition of the Guidelines for the Management of Hemophilia, replacing the 2nd Edition published in...